All manuscripts
Publications CAR T Cells G-Rex®100M G-Rex®500M

CAR-T cell expansion platforms yield distinct T cell differentiation states

Published Journal Cytotherapy

Share
No image preview

Overview

This study compares CAR-T expansion in Prodigy, Xuri, G-Rex®, and bags. G-Rex® (500M) cultures yielded effector memory-enriched cells. Hypoxic culture in G-Rex® increased the proportion of naïve/stem central memory-like cells, suggesting oxygenation is a key factor in T cell differentiation during manufacturing.

What this paper found

Under identical media, stimulation, culture length and donor cells, four CAR-T expansion platforms produced cells in different differentiation states. FGFR4 CAR-T cells from four healthy donors were grown for 14 days in bags, a 5 L G-Rex®, a Xuri W25 or a CliniMACS Prodigy. Bags gave the highest mean fold expansion (481.2), the Prodigy the lowest output (4.2 × 10^9 cells), and the G-Rex® 9.5 × 10^9 cells with less variability than the Xuri. On day 14, 46.6% of Prodigy cells were Tn/scm-like, against 15.6% in bags and 12.6% in G-Rex®. Dissolved oxygen in the Prodigy fell to 97 mmHg; culturing bag and G-Rex® cells at 1% O2 for 9 days raised Tn/scm-like cells to 78.7% and 62.7%, but reduced expansion.

Note: Cells came from healthy donors only; the authors note that the effect of hypoxia on phenotype should be tested with additional donor and patient material to judge its relevance to specific diseases.

In conclusion, we demonstrate that T cell differentiation states are affected by platform selection and suggest that hypoxia is a potential mechanism to control differentiation. — Hannah W. Song, Michaela Prochazkova, Lipei Shao, Roshini Traynor, Sarah Underwood, Mary Black, Vicki Fellowes, Rongye Shi, Marie Pouzolles, Hsien-Chao Chou, Adam T. Cheuk, Naomi Taylor, Ping Jin, Robert P. Somerville, David F. Stroncek, Javed Khan, Steven L. Highfill, Cytotherapy

Study details

Authors
Hannah W. Song, Michaela Prochazkova, Lipei Shao, Roshini Traynor, Sarah Underwood, Mary Black, Vicki Fellowes, Rongye Shi, Marie Pouzolles, Hsien-Chao Chou, Adam T. Cheuk, Naomi Taylor, Ping Jin, Robert P. Somerville, David F. Stroncek, Javed Khan, Steven L. Highfill
Institution
Department of Transfusion Medicine, Center for Cellular Engineering, National Institutes of Health, Bethesda, MD, USA · Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA · Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA · Genomics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Journal
Cytotherapy
Year
2024
PMID / PMC
PMID: 38625071
G-Rex® model(s)
G-Rex®100M, G-Rex®500M
Cell type(s)
CAR T Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

In the platform comparison, bag-transduced CAR-T cells were seeded on day 5 into a single-use GRex-500M-CS (5 L culture capacity) at 200 × 10^6 viable cells in 1500 mL of Tex-CART-200 medium, with 1500 mL more added on days 8 and 11 (4500 mL at harvest). On day 14 the cells were volume-reduced and collected with the GatheRex system; the G-Rex® arm averaged 9.5 × 10^9 cells, with less variability than the Xuri. For the high-density and hypoxia experiments, 1 L G-Rex® vessels were used: 200 × 10^6 cells with daily media exchange, or 40 × 10^6 cells in 300 mL fed to 900 mL, with some cultures moved to a 1% O2 hypoxystation on day 5, 8 or 11.

Ecosystem products: GatheRex

Explore related

Full citation

Song HW, Prochazkova M, Shao L, et al. CAR-T cell expansion platforms yield distinct T cell differentiation states. Cytotherapy. 2024;26(7):757-768.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →